Novo Holdings Soonto Acquire Majority Stake in Single Use Support

Novo Holdings Soonto Acquire Majority Stake in Single Use Support

By, Admin 16 May 2024

Novo Holdings to acquire majority stake in life science tools company, Single Use Support

Overview

Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10% and Danaher which will retain 20% of the share capital.

Single Use Support

  • Founded in 2017 in Kufstein, Austria by Johannes Kirchmair and Thomas Wurm, Single Use Support is at the forefront of transforming the production process for advanced pharmaceutical modalities with its equipment and consumables used in the bioprocessing value chain. 
  • With a focus on solutions for biological drug substances, cell and gene therapies, and mRNA vaccines, the company’s customers include leading pharma companies, biotech companies and CDMOs.

Market trend- Single Use Support’s products have rapidly gained widespread adoption by enhancing operational efficiency, minimising leakage, and effectively mitigating contamination risks in the pharmaceutical production process.

Words from Novo Holdings

  • Johan Hueffer, senior partner, Principal Investments, Novo Holdings, said: “We are pleased to announce the acquisition of a majority stake in Single Use Support, a leading provider of advanced fluid management solutions. This transaction marks an important and complimentary addition to our fast-growing life science tools & diagnostics portfolio and represents our first control investment in the DACH region, a vital hub for life sciences. This investment also underscores our commitment to advancing leading healthcare therapies and technologies.”
  • Tuomas Toiviainen, partner, Principal Investments, Novo Holdings, added: “We are excited to partner with existing shareholders and management to support the next phase of growth and drive further innovation in the rapidly expanding bioprocessing market. This acquisition demonstrates our expertise and investment focus in backing high-quality life science tools companies. We look forward to working with the Single Use Support management team and employees who share our passion for innovation in the life science space.”

From Single Use Support and Board Members

Johannes Kirchmair and Thomas Wurm, founders of Single Use Support and board members, said: “Welcoming Novo Holdings as a partner marks a significant milestone in our growth journey at Single Use Support. We take pride in having nurtured and developed our company into a key player in the life sciences sector. As we embark on this new chapter, we are enthusiastic about the prospects of partnering with Novo Holdings, a global leader in life science investments. The collaboration aligns perfectly with our mission and complements our existing partnership with Danaher, which will continue as a valued partner. Together, we look forward to advancing our impact and innovation in the life sciences industry.”

Words from Vice President: Danaher

Chris Riley, executive vice president, Biotechnology Group, Danaher, said: “We are pleased to continue our involvement in Single Use Support and to partner with Novo Holdings as we take the company to the next level. At Danaher, we are focused on leveraging the power of science and technology to meaningfully improve human health, which makes Novo Holdings a very good long-term partner for us in the collaboration at Single Use Support and beyond.”

Words from CEO: Danaher

Christian Praxmarer, CEO, Single Use Support, said: “Novo Holdings is joining us at a crucial moment as we prepare to further strengthen our global footprint, focusing on markets outside of Europe such as the US and Asia, and to engage with new customers. With significant insights into the life science tools sector and a comprehensive industry network, I am excited to work alongside Novo Holdings and make new strides in our shared mission of bringing better treatments to patients.”

Support teams for Novo Holdings

The transaction is subject to regulatory approvals. Kromann Reumert, DORDA, Linklaters and Wilson Sonsini served as legal advisors and William Blair served as financial advisor to Novo Holdings. E+H served as legal advisor while Jefferies LLC served as financial advisor to Single Use Support.

Novo Holdings

  • Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. 
  • The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!